Various effects of AAV9-mediated βARKct gene therapy on the heart in dystrophin-deficient (mdx) mice and δ-sarcoglycan-deficient (Sgcd-/-) mice
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Neuromuscular Disorders
- Vol. 29 (3) , 231-241
Abstract
No abstract availableKeywords
Funding Information
- Bundesministerium für Forschung, Technologie und Raumfahrt
- National Institutes of Health (P01 HL075443, P01 HL108806, R37 HL061690)
- Deutsches Zentrum für Herz-Kreislaufforschung
This publication has 43 references indexed in Scilit:
- Targeting GRK2 by gene therapy for heart failure: benefits above β-blockadeGene Therapy, 2012
- G protein-coupled receptor kinases in normal and failing myocardiumFrontiers in Bioscience-Landmark, 2011
- Intolerance to β-Blockade in a Mouse Model of δ-Sarcoglycan-Deficient Muscular Dystrophy CardiomyopathyEuropean Journal of Heart Failure, 2010
- Consequences of Disrupting the Dystrophin-Sarcoglycan Complex in Cardiac and Skeletal MyopathyTrends in Cardiovascular Medicine, 2007
- Genetic Predictors and Remodeling of Dilated Cardiomyopathy in Muscular DystrophyCirculation, 2005
- Cardiomyopathy in muscular dystrophiesCurrent Opinion in Neurology, 2003
- Seven-transmembrane-spanning receptors and heart functionNature, 2002
- Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failureProceedings of the National Academy of Sciences, 2001
- β-Adrenergic Receptor Blockade in Chronic Heart FailureCirculation, 2000
- Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted miceProceedings of the National Academy of Sciences, 1998